Opioid Agonist Therapy
A new guideline recommends opioid agonist therapy with buprenorphine-naloxone as first-line for the treatment of opioid use disorder.
Slow-Release Oral Morphine, a Promising Opioid Agonist Therapy Alternative to Buprenorphine, MethadoneJanuary 11, 2018
Slow-release oral morphine may be a valuable tool to help reduce the number of deaths from opioid-related overdose.
Immediate access to opioid agonist treatment for patients presenting with opioid use disorder may provide greater health benefits at less cost than observed standard of care.
A small fraction of prescriptions for Medicare patients are for opioid agonist therapy, despite higher rates of abuse.
Clinical Pain Advisor Articles
- Radiofrequency Denervation Efficacious in Treating Thoracic Zygapophyseal Joint Pain
- Prescribed Opioids Difficulties Scale Effective for Assessing Concerns of Patients With Chronic Pain
- Predictors of Opioid Overdose in High-Risk Users
- Optimal Strategies for Opioid Weaning After Ambulatory Surgery
- Emergency Physicians Offer Recommendations for Identifying and Managing Opioid Use Disorder
- Consensus Guidelines for the Use of Intravenous Ketamine for Chronic Pain
- Pain Societies Issue Guidelines on Use of Ketamine for the Management of Acute Pain
- Labor Epidural Analgesia Linked to Reduced Likelihood of Successful Breastfeeding
- Novel Oral Treatment Safe, Effective for Migraine Headache Relief
- DFN-02 Nasal Spray Safe, Effective for Acute Treatment of Episodic Migraine
- Men With Migraines May Have Increased Serum Estradiol, Androgen Deficiency
- Fremanezumab Effective in Reversion of Chronic Migraine to Episodic Migraine
- Endocannabinoids May Be Elevated in Women With Fibromyalgia
- Putting Patients in the Physician's Seat: Smartphone Technology Is Changing the Healthcare Landscape
- Cardiovascular, Psychiatric Comorbidity Patterns Evident in Migraine